Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $53.6 million.

  • Mereo BioPharma's Liabilities and Shareholders Equity fell 3960.07% to $53.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.9 million, marking a year-over-year decrease of 1508.76%. This contributed to the annual value of $76.4 million for FY2024, which is 1487.39% up from last year.
  • Latest data reveals that Mereo BioPharma reported Liabilities and Shareholders Equity of $53.6 million as of Q3 2025, which was down 3960.07% from $62.6 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Liabilities and Shareholders Equity high stood at $202.6 million for Q2 2021, and its period low was $53.6 million during Q3 2025.
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $76.9 million (2022), whereas its average is $96.2 million.
  • In the last 5 years, Mereo BioPharma's Liabilities and Shareholders Equity skyrocketed by 10502.25% in 2021 and then tumbled by 5457.29% in 2022.
  • Quarter analysis of 5 years shows Mereo BioPharma's Liabilities and Shareholders Equity stood at $170.4 million in 2021, then crashed by 54.57% to $77.4 million in 2022, then dropped by 14.1% to $66.5 million in 2023, then rose by 14.87% to $76.4 million in 2024, then dropped by 29.83% to $53.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $53.6 million for Q3 2025, versus $62.6 million for Q2 2025 and $68.3 million for Q1 2025.